Shaanxi Kanghui Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Shaanxi Kanghui Pharmaceutical's earnings have been declining at an average annual rate of -53.8%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 9.3% per year.
Key information
-53.8%
Earnings growth rate
-53.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 9.3% |
| Return on equity | -6.1% |
| Net Margin | -4.9% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Shaanxi Kanghui Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 677 | -33 | 167 | 11 |
| 31 Dec 23 | 673 | -26 | 166 | 11 |
| 30 Sep 23 | 589 | -70 | 175 | 10 |
| 30 Jun 23 | 518 | -64 | 179 | 13 |
| 31 Mar 23 | 498 | -64 | 177 | 13 |
| 31 Dec 22 | 492 | -63 | 181 | 12 |
| 30 Sep 22 | 483 | 31 | 171 | 14 |
| 30 Jun 22 | 472 | 35 | 167 | 11 |
| 31 Mar 22 | 464 | 36 | 172 | 10 |
| 31 Dec 21 | 443 | 36 | 169 | 10 |
| 30 Sep 21 | 457 | 26 | 170 | 11 |
| 30 Jun 21 | 452 | 33 | 165 | 11 |
| 31 Mar 21 | 428 | 36 | 155 | 10 |
| 31 Dec 20 | 414 | 34 | 144 | 10 |
| 30 Sep 20 | 419 | 40 | 144 | 8 |
| 30 Jun 20 | 422 | 40 | 140 | 8 |
| 31 Mar 20 | 427 | 39 | 141 | 8 |
| 31 Dec 19 | 431 | 43 | 143 | 8 |
| 30 Sep 19 | 432 | 55 | 135 | 7 |
| 30 Jun 19 | 399 | 52 | 127 | 6 |
| 31 Mar 19 | 388 | 56 | 127 | 7 |
| 31 Dec 18 | 376 | 56 | 123 | 7 |
| 30 Sep 18 | 383 | 60 | 133 | 7 |
| 30 Jun 18 | 379 | 66 | 128 | 10 |
| 31 Mar 18 | 383 | 64 | 128 | 8 |
| 31 Dec 17 | 367 | 63 | 127 | 7 |
| 30 Sep 17 | 384 | 66 | 133 | 4 |
| 30 Jun 17 | 386 | 65 | 136 | 0 |
| 31 Mar 17 | 385 | 65 | 135 | 0 |
| 31 Dec 16 | 382 | 65 | 133 | 0 |
| 31 Dec 15 | 380 | 62 | 135 | 0 |
| 31 Dec 14 | 376 | 63 | 132 | 0 |
| 31 Dec 13 | 328 | 56 | 114 | 0 |
Quality Earnings: 603139 is currently unprofitable.
Growing Profit Margin: 603139 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603139 is unprofitable, and losses have increased over the past 5 years at a rate of 53.8% per year.
Accelerating Growth: Unable to compare 603139's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 603139 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.1%).
Return on Equity
High ROE: 603139 has a negative Return on Equity (-6.05%), as it is currently unprofitable.